PLoS ONE (Jan 2011)

Percutaneous cryoablation of pulmonary metastases from colorectal cancer.

  • Yoshikane Yamauchi,
  • Yotaro Izumi,
  • Masafumi Kawamura,
  • Seishi Nakatsuka,
  • Hideki Yashiro,
  • Norimasa Tsukada,
  • Masanori Inoue,
  • Keisuke Asakura,
  • Hiroaki Nomori

DOI
https://doi.org/10.1371/journal.pone.0027086
Journal volume & issue
Vol. 6, no. 11
p. e27086

Abstract

Read online

OBJECTIVE: To evaluate the safety and efficacy of cryoablation for metastatic lung tumors from colorectal cancer. METHODS: The procedures were performed on 24 patients (36-82 years of age, with a median age of 62; 17 male patients, 7 female patients) for 55 metastatic tumors in the lung, during 30 sessions. The procedural safety, local progression free interval, and overall survival were assessed by follow-up computed tomographic scanning performed every 3-4 months. RESULTS: The major complications were pneumothorax, 19 sessions (63%), pleural effusion, 21 sessions (70%), transient and self-limiting hemoptysis, 13 sessions (43%) and tract seeding, 1 session (3%). The 1- and 3-year local progression free intervals were 90.8% and 59%, respectively. The 3-years local progression free intervals of tumors ≤15 mm in diameter was 79.8% and that of tumors >15 mm was 28.6% (p = 0.001; log-rank test). The 1- and 3-year overall survival rates were 91% and 59.6%, respectively. CONCLUSION: The results indicated that percutaneous cryoablation is a feasible treatment option. The local progression free interval was satisfactory at least for tumors that were ≤15 mm in diameter.